CDMO / CMOFounded 2011
Samsung Biologics Co., Ltd.
Songdo, Incheon, Incheon, South Korea
A biologics-focused CDMO built by Samsung Group that provides mammalian-cell process development and large-scale commercial biomanufacturing, including antibody-drug conjugates, and has scaled quickly into one of the industry's largest bioreactor-capacity operators.
- Segment
- CDMO / CMO
- Headquarters
- Songdo, Incheon, Incheon, South Korea
- Founded
- 2011
- Website
- www.samsungbiologics.com
Notable facts
- Established April 22, 2011 as a Samsung Group biotech venture; Samsung C&T and Samsung Electronics remain its two largest shareholders.
- Operates five manufacturing plants in Songdo with combined bioreactor capacity of roughly 785,000 liters after Plant 5 came online in 2025.
- Opened a dedicated antibody-drug conjugate (ADC) manufacturing facility in Songdo in March 2025.
- As of mid-2024 reported active manufacturing partnerships with 16 of the world's 20 largest biopharmaceutical companies, including Pfizer, GSK, Eli Lilly, AstraZeneca, and Bristol-Myers Squibb.
Sourcing guides
Sources. This profile is compiled from public reference data, WebSearch-verified against source 1. Data as of 2026-07-14. See methodology.
Sourcing a vendor in this segment today? We connect clinical operations, regulatory, and procurement teams with qualified cdmo / cmo vendors.
Request vendors